Antibodies
18 October 2007
Merck Serono Announces Joint Agreement with ImClone and Bristol-Myers Squibb for Erbitux in Japan17 October 2007
Scientists Show Monoclonal Antibody Leads to Repair of Myelin Sheath in Laboratory Study of Multiple Sclerosis16 October 2007
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis12 October 2007
WILEX’ second product enters Phase III trial: IND approval from FDA for registration trial with CA9-SCAN12 October 2007
Genmab Amends HuMax-CD4 Pivotal Study in CTCL12 October 2007
Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy9 October 2007
MorphoSys Enters Therapeutic Research Collaboration on Novel Target Molecule with Genesis Research5 October 2007
ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis4 October 2007
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis4 October 2007
Crucell presents Phase I results rabies antibody cocktail showing safety and ability to protect3 October 2007
Roche Files CTA for Third Genmab Antibody1 October 2007
Preclinical Study Published in Nature Medicine Shows Anti-LINGO-1 AntibodyPromotes Remyelination28 September 2007
Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study28 September 2007
Crucell discovers human monoclonal antibodies for the prevention and treatment of the avian flu virus27 September 2007
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis26 September 2007
Abbott and Eisai submit application for adalimumab, the only fully human monoclonal anti-TNFalpha antibody, to treat psoriasis26 September 2007
New Biomarker Data Links KRAS Gene to Vectibix(TM) Clinical Response22 September 2007
Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European UnionNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports